Rheumatoid arthritis is a progressive inflammatory disease that affects 24 million people worldwide, including 500,000 Australians. Despite advances in drug therapies, 40% of patients fail the first line of therapy and 20% fail the second line of therapy, and these drug-resistant patients remain without hope of relief from painful, debilitating symptoms.

Using electricity to alter the activity of nerves, dubbed ‘electroceutical therapy’, has demonstrated success in the treatment of inflammatory diseases. Our researchers are developing electroceutical therapy for the treatment of rheumatoid arthritis by developing bionic technology that activates the body’s natural inflammatory reflex by targeting the vagus nerve.

Further information

Click here to download our factsheet.

Research team

Program leader: Dr Sophie Payne

Team members: A/Prof James Fallon

Collaborators: A/Prof Evange Romas